- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02395029
Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD (PMD-MSC-PD-01)
Evaluate the Safety and Feasibility of Injecting Placental Matrix-Derived Mesenchymal Stem Cells Into the Penis to Treat the Symptoms of Peyronie's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Symptoms of Peyronie's disease include penile pain and curvature of the penis that prevents penetration and/or causes erectile dysfunction (ED). It is characterized by plaques that form along the top or bottom side of the penis inside the tunica albuginea; the plaque begins as a localized inflammation then develops into a hardened scar. Cases can range from mild to severe. In several cases, the hardened plaque reduces flexibility, causing the penis to curve during erection. The sexual problems as a result can lower a man's self-esteem and interfere with a couple's physical and emotional relationship.
The cause is unknown; however, possibilities include trauma, inherited conditions, Vitamin E deficiency, diabetes, and vascular disease.
Conservative treatments used in the acute phase (initial onset of symptoms) include oral therapies. Vitamin E and antioxidants can decrease the build-up of harmful chemicals that can cause injury to tissue. It is often used as the traditional treatment; it is inexpensive and with proper dosing, there are minimal side effects. Other oral agents include Potaba (aminobenzoates potassium); however, it is expensive ($1000 per year) and has associated gastrointestinal side effects.
Other therapies involve injections directly in the plaques (intralesional) with chemicals such as collagenase or calcium-channel blockers.
Surgical therapies are offered once the disease is stable (symptoms present for one year). Invasive surgical options consist of correction of the penile curvature or the placement of a penile prosthesis to straighten the penis to allow for erections.
Mesenchymal stem cells (MSCs) have been used for a variety of medical treatments to repair and regenerate acute and chronically damaged tissues. These cells have the potential to repair human tissue by forming cells of mesenchymal origin, such as cartilage, bone, fat, muscle, and blood vessels. Most research has focused on bone marrow derived stem cells (BMC) however the process for harvesting the cells is invasive, painful, and yields a low cell count. The human placenta offers an alternative source form MSCs. Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs) are compromised of a novel cellular repair matrix derived from placental mesenchyme. Mesenchyme is the meshwork of embryonic connective tissue in the mesoderm, from which are formed the muscular and connective tissues of the body and also the blood vessels. PMD-MSCs provide the extracellular matrix viable mesenchymal stem cells (MSCs) that coordinate the tissue repair process, regenerative growth factors, and anti-inflammatory cytokines required to regenerate the damaged vasculature of the penile corpora.
The research proposed here will establish the safety and feasibility of utilizing intracavernosal, intralesional injections of PMD-MSCs to treat Peyronie's disease with the intent of avoiding surgery.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Coral Springs, Florida, United States, 33076
- Z Urology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- acquired penile curvature >15 and <90 degrees associated with palpable penile plaque on physical examination
- 1 or 2 penile plaque at screening
Exclusion Criteria:
- taking the medication Coumadin
- unable to achieve adequate erection with penile injection to access degree of curvature
- undergone definitive treatment for prostate cancer, bladder cancer, or other pelvic malignancies including surgery, external beam radiation therapy, brachytherapy, cryotherapy
- prior history of prostate cancer, hematologic disorders, chronic liver disease including cirrhosis and hepatitis C, disorders affecting the immune system, including infection with the human immunodeficiency virus, or psychiatric disorder including major depression, schizophrenia, bipolar disease
- history of cerebrovascular accident, history of deep venous thrombosis within the past 5 years or history of untreated or severe sleep apnea
- clinically significant abnormal lab results that would put the subject at increased risk or compromise the integrity of the study data, in the opinion of the investigator
- received any other investigational drug within 30 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Injection of PMD-MSCs into the penis
Subjects will receive an initial injection of 1.0cc of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs).
Subjects will be eligible for re-injection at 3 months and/or 6 months as determined by the clinician based on ultrasound guided measurements of penile plaque(s) post treatment and on patient reported treatment satisfaction.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Peak Systolic Velocity without trimix (cm/s)
Time Frame: Baseline
|
Baseline
|
Peak Systolic Velocity without trimix (cm/s)
Time Frame: 6 weeks
|
6 weeks
|
Peak Systolic Velocity without trimix (cm/s)
Time Frame: 3 months
|
3 months
|
Peak Systolic Velocity without trimix (cm/s)
Time Frame: 6 months
|
6 months
|
Peak Systolic Velocity without trimix (cm/s)
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
End Diastolic Velocity without trimix (cm/s)
Time Frame: Baseline
|
Baseline
|
End Diastolic Velocity without trimix (cm/s)
Time Frame: 6 weeks
|
6 weeks
|
End Diastolic Velocity without trimix (cm/s)
Time Frame: 3 months
|
3 months
|
End Diastolic Velocity without trimix (cm/s)
Time Frame: 6 months
|
6 months
|
End Diastolic Velocity without trimix (cm/s)
Time Frame: 12 months
|
12 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
International Index of Erectile Function (IIEF)
Time Frame: 6 weeks
|
6 weeks
|
Peak Systolic Velocity with trimix (cm/s)
Time Frame: Baseline
|
Baseline
|
Peak Systolic Velocity with trimix (cm/s)
Time Frame: 6 weeks
|
6 weeks
|
Peak Systolic Velocity with trimix (cm/s)
Time Frame: 3 months
|
3 months
|
Peak Systolic Velocity with trimix (cm/s)
Time Frame: 6 months
|
6 months
|
Peak Systolic Velocity with trimix (cm/s)
Time Frame: 12 months
|
12 months
|
End Diastolic Velocity with trimix (cm/s)
Time Frame: Baseline
|
Baseline
|
End Diastolic Velocity with trimix (cm/s)
Time Frame: 6 weeks
|
6 weeks
|
End Diastolic Velocity with trimix (cm/s)
Time Frame: 3 months
|
3 months
|
End Diastolic Velocity with trimix (cm/s)
Time Frame: 6 months
|
6 months
|
End Diastolic Velocity with trimix (cm/s)
Time Frame: 12 months
|
12 months
|
Rigidity test (Pass or Fail)
Time Frame: Baseline
|
Baseline
|
Rigidity test (Pass or Fail)
Time Frame: 6 weeks
|
6 weeks
|
Rigidity test (Pass or Fail)
Time Frame: 3 months
|
3 months
|
Rigidity test (Pass or Fail)
Time Frame: 6 months
|
6 months
|
Rigidity test (Pass or Fail)
Time Frame: 12 months
|
12 months
|
Stretched Penile Length before trimix (cm/s)
Time Frame: Baseline
|
Baseline
|
Stretched Penile Length before trimix (cm/s)
Time Frame: 6 weeks
|
6 weeks
|
Stretched Penile Length before trimix (cm/s)
Time Frame: 3 months
|
3 months
|
Stretched Penile Length before trimix (cm/s)
Time Frame: 6 months
|
6 months
|
Stretched Penile Length before trimix (cm/s)
Time Frame: 12 months
|
12 months
|
Post Penile Width with trimix
Time Frame: Baseline
|
Baseline
|
Post Penile Width with trimix
Time Frame: 6 weeks
|
6 weeks
|
Post Penile Width with trimix
Time Frame: 3 months
|
3 months
|
Post Penile Width with trimix
Time Frame: 6 months
|
6 months
|
Post Penile Width with trimix
Time Frame: 12 months
|
12 months
|
International Index of Erectile Function (IIEF)
Time Frame: Baseline
|
Baseline
|
International Index of Erectile Function (IIEF)
Time Frame: 3 months
|
3 months
|
International Index of Erectile Function (IIEF)
Time Frame: 6 months
|
6 months
|
International Index of Erectile Function (IIEF)
Time Frame: 12 months
|
12 months
|
#1 Penile Plaque (Location) Size (mm^3)
Time Frame: Baseline
|
Baseline
|
#1 Penile Plaque (Location) Size (mm^3)
Time Frame: 6 weeks
|
6 weeks
|
#1 Penile Plaque (Location) Size (mm^3)
Time Frame: 3 months
|
3 months
|
#1 Penile Plaque (Location) Size (mm^3)
Time Frame: 6 months
|
6 months
|
#1 Penile Plaque (Location) Size (mm^3)
Time Frame: 12 months
|
12 months
|
#2 Penile Plaque (Location) Size (mm^3)
Time Frame: Baseline
|
Baseline
|
#2 Penile Plaque (Location) Size (mm^3)
Time Frame: 6 weeks
|
6 weeks
|
#2 Penile Plaque (Location) Size (mm^3)
Time Frame: 3 months
|
3 months
|
#2 Penile Plaque (Location) Size (mm^3)
Time Frame: 6 months
|
6 months
|
#2 Penile Plaque (Location) Size (mm^3)
Time Frame: 12 months
|
12 months
|
#3 Penile Plaque (Location)Size (mm^3)
Time Frame: Baseline
|
Baseline
|
#3 Penile Plaque (Location)Size (mm^3)
Time Frame: 6 weeks
|
6 weeks
|
#3 Penile Plaque (Location)Size (mm^3)
Time Frame: 3 months
|
3 months
|
#3 Penile Plaque (Location)Size (mm^3)
Time Frame: 6 months
|
6 months
|
#3 Penile Plaque (Location)Size (mm^3)
Time Frame: 12 months
|
12 months
|
Penile Curvature Angle (degrees)
Time Frame: Baseline
|
Baseline
|
Penile Curvature Angle (degrees)
Time Frame: 6 weeks
|
6 weeks
|
Penile Curvature Angle (degrees)
Time Frame: 3 months
|
3 months
|
Penile Curvature Angle (degrees)
Time Frame: 6 months
|
6 months
|
Penile Curvature Angle (degrees)
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael P. Zahalsky, M.D., Z Urology
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PMD-MSC-PD-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peyronie's Disease
-
Men's Health BostonCompleted
-
University Hospital, MontpellierCompletedPeyronie DiseaseFrance
-
Hopital FochDornier MedTech SystemsRecruitingPenile Diseases | Peyronie DiseaseFrance
-
King's College LondonCompletedPeyronie DiseaseUnited Kingdom
-
Odense University HospitalUnknown
-
Endo PharmaceuticalsCompletedPeyronie's DiseaseUnited States, Denmark, France, Germany, Italy, New Zealand, Spain, Sweden, United Kingdom
-
Endo PharmaceuticalsCompleted
-
University Hospital, ToulouseRecruitingPeyronie DiseaseFrance
-
University of Roma La SapienzaRecruitingPeyronie DiseaseItaly
Clinical Trials on Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)
-
Melissa MarchandCompletedErectile DysfunctionUnited States
-
The Cleveland ClinicCase Western Reserve UniversityWithdrawnInflammatory Bowel Diseases | Crohn's Disease | Pouchitis | Ulcerative Colitis Chronic | Pouch, IlealUnited States
-
The Cleveland ClinicWithdrawnFistula | Crohn's Disease | Anal Fistula | Pouch, Ileal | Pouches, Ileoanal
-
Guangdong Provincial Hospital of Traditional Chinese...CompletedPsoriasis | Drug Effect | Drug Toxicity | Mesenchymal Stromal CellsChina
-
Affiliated Hospital to Academy of Military Medical...Unknown
-
Institute of Hematology & Blood Diseases HospitalActive, not recruitingThrombocytopenia | Mesenchymal Stem CellsChina
-
Mayo ClinicCompletedConnective Tissue Diseases | Interstitial Lung DiseaseUnited States
-
Instituto de Investigación Hospital Universitario...Instituto de Salud Carlos III; Universidad Carlos III Madrid (TERMeG); St John... and other collaboratorsUnknownEpidermolysis Bullosa Dystrophica, RecessiveSpain
-
National University of MalaysiaCytopeutics Sdn. Bhd.UnknownIschemic Dilated CardiomyopathyMalaysia
-
Nanfang Hospital of Southern Medical UniversityPeking University People's Hospital; Sun Yat-sen University; Guangzhou First... and other collaboratorsUnknownChronic Graft-versus-host DiseaseChina